Combined polychemotherapy in the treatment of primitive XXXX of the "non-oat cell" type.

@entity1 @entity1665 @entity137 @entity390 @entity882 @entity391 @entity2 @entity8442 @entity5713 @entity1210
Forty-one @entity1 (30 males, 11 females; mean age 49.7 years) with diagnosis of the "non-oat cell" type of @entity2 were studied. All @entity1 were included in a randomized treatment design (regimens A and B) and completed six full cycles of polychemotherapy. Only 28 of the 41 @entity1 proved evaluable. The performance status was 0-2 in 20 subjects (71.4%) and 3-4 in 8 (28.6%). The total number of @entity1 achieving partial and complete responses was 20 (71.4%), of whom 14 (70%) received CDDP and the other 6 DDR. A progression of the disease was seen in 8 @entity1 (28.6%), of whom 5 (62.5%) received DDR and the other 3 (37.5%) CDDP. An increase in body weight (3-8 kg) was observed in 15 @entity1 (53.6%). Twenty-four of the 28 @entity1 (85.7%) had a subjective feeling of well-being throughout the 6 cycles of chemotherapy. @entity390 and @entity391 and @entity1665 were the most frequent side-effects. The most important complications were @entity8442 in 2 cases and a darkish manifestation in forearm and hand tissue due to @entity5713 extravasation in another 2 cases. @entity137 was found to be acceptable: @entity1210 (less than 3.000) in 30 @entity1 (73.2%); and @entity882 (less than 100.000) in 12 @entity1 (29.2%), which proved reversible. Some modalities relative to treatment schemes and the incorporation of additional agents are discussed.
